SANDOZ ALENDRONATE/CHOLECALCIFEROL TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

ALENDRONIC ACID (ALENDRONATE SODIUM TRIHYDRATE); VITAMIN D3 (CHOLECALCIFEROL)

Доступна з:

SANDOZ CANADA INCORPORATED

Код атс:

M05BB03

ІПН (Міжнародна Ім'я):

ALENDRONIC ACID AND CHOLECALCIFEROL

Дозування:

70MG; 5600UNIT

Фармацевтична форма:

TABLET

Склад:

ALENDRONIC ACID (ALENDRONATE SODIUM TRIHYDRATE) 70MG; VITAMIN D3 (CHOLECALCIFEROL) 5600UNIT

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

4

Тип рецепту:

Prescription

Терапевтична области:

VITAMIN D

Огляд продуктів:

Active ingredient group (AIG) number: 0251575002; AHFS:

Статус Авторизація:

CANCELLED POST MARKET

Дата Авторизація:

2023-07-28

Характеристики продукта

_ _
_Sandoz Alendronate/Cholecalciferol _
_Page 1 of 46_
PRODUCT MONOGRAPH
Pr
SANDOZ ALENDRONATE/CHOLECALCIFEROL
alendronate sodium/cholecalciferol tablets
70 mg alendronate (as alendronate sodium) + 140 mcg cholecalciferol
(5600 IU vitamin D
3
)
Bone Metabolism Regulator and Vitamin D
Sandoz Canada Inc.
145 Jules-Léger
Boucherville, Québec
J4B 7K8
Date of Revision:
July 18, 2017
Submission Control No: 206959
_ _
_Sandoz Alendronate/Cholecalciferol. _
_Page 2 of 46_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
15
OVERDOSAGE
................................................................................................................
17
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 17
STORAGE AND STABILITY
.........................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 23
PART II: SCIENTIFIC INFORMATION
..............................................................................
24
PHARMACEUTICAL INFORMATION
.........................................................................
24
CLINICAL TRIALS
.........